Butzin-Dozier Zachary, Ji Yunwen, Wang Lin-Chiun, Anzalone A Jerrod, Coyle Jeremy, Phillips Rachael V, Patel Rena C, Sun Jing, Hurwitz Eric, Deshpande Sarang, Shi Junming Seraphina, Mertens Andrew, van der Laan Mark J, Colford John M, Hubbard Alan E
School of Public Health, University of California, Berkeley, Berkeley, CA USA.
University of Nebraska Medical Center, Omaha, NE USA.
medRxiv. 2025 Apr 23:2025.04.22.25326224. doi: 10.1101/2025.04.22.25326224.
Long COVID is a debilitating condition that impacts millions of Americans, but patients and clinicians have little information on how to prevent this disorder. Vaccination is a vital tool in preventing acute COVID-19 and may confer additional protection against Long COVID. There is limited evidence regarding the optimal timing of COVID-19 vaccination (i.e., vaccination schedule) to minimize the risk of Long COVID.
We applied Longitudinal Targeted Maximum Likelihood Estimation to electronic health record (EHR) data from a retrospective cohort of patients vaccinated against COVID-19 between December 2021 and September 2022. We evaluated the association between binary COVID-19 vaccination status (two or more doses vs. zero doses) and 12-month Long COVID risk among patients diagnosed with acute COVID-19 between December 2021 and September 2022. In addition, we compared the 12-month cumulative risk of Long COVID (ICD-10 code U09.9) among patients diagnosed with acute COVID-19 one to three months after vaccination, three to five months after vaccination, or five to seven months after vaccination while adjusting for relevant high-dimensional baseline and time-dependent covariates.
We analyzed EHR data from a retrospective cohort of 1,558,018 patients. In our binary cohort ( = 519,980), we found that vaccinated patients had a lower risk of Long COVID than unvaccinated patients (adjusted marginal risk ratio 0.84 (0.81, 0.88)). In our longitudinal cohort ( = 1,085,291), we did not find a significant difference in Long COVID risk comparing patients who were diagnosed with acute COVID-19 one to three months after vaccination versus patients who were diagnosed with COVID-19 three to five months (adjusted marginal risk ratio 0.93 (95% CI 0.62, 1.41) or 5 to 7 months (adjusted marginal risk ratio 1.06 (95% CI 0.72, 1.56)) after vaccination.
We found that COVID-19 vaccination before SARS-CoV-2 infection was protective against Long COVID, and we did not find that this protection significantly waned within 7 months after vaccination. These findings suggest that COVID-19 vaccination protects against Long COVID.
长期新冠是一种使人衰弱的病症,影响着数百万美国人,但患者和临床医生对于如何预防这种疾病知之甚少。接种疫苗是预防急性新冠病毒病的重要工具,可能对预防长期新冠提供额外保护。关于新冠病毒病疫苗接种的最佳时间(即接种计划)以将长期新冠风险降至最低的证据有限。
我们将纵向靶向最大似然估计应用于2021年12月至2022年9月期间接种新冠病毒疫苗的回顾性队列患者的电子健康记录(EHR)数据。我们评估了2021年12月至2022年9月期间被诊断为急性新冠病毒病的患者中,二元新冠病毒疫苗接种状态(两剂或更多剂次与零剂次)与12个月长期新冠风险之间的关联。此外,我们比较了在接种疫苗后1至3个月、3至5个月或5至7个月被诊断为急性新冠病毒病的患者中,长期新冠(国际疾病分类第十版代码U09.9)的12个月累积风险,同时调整相关的高维基线和随时间变化的协变量。
我们分析了1,558,018例患者回顾性队列的电子健康记录数据。在我们的二元队列(n = 519,980)中,我们发现接种疫苗的患者患长期新冠的风险低于未接种疫苗的患者(调整后的边际风险比为0.84(0.81, 0.88))。在我们的纵向队列(n = 1,085,291)中,我们没有发现接种疫苗后1至3个月被诊断为急性新冠病毒病的患者与接种疫苗后3至5个月(调整后的边际风险比为0.93(95%置信区间0.62, 1.41))或5至7个月(调整后的边际风险比为1.06(95%置信区间0.72, 1.56))被诊断为新冠病毒病的患者在长期新冠风险上有显著差异。
我们发现,在感染严重急性呼吸综合征冠状病毒2之前接种新冠病毒疫苗对预防长期新冠有保护作用,并且我们没有发现这种保护作用在接种疫苗后7个月内显著减弱。这些发现表明,新冠病毒疫苗接种可预防长期新冠。